SPRING

Why some RNA drugs work better than others

Retrieved on: 
Wednesday, March 6, 2024

CSHL Associate Professor Justin Kinney, Krainer, and postdoc Yuma Ishigami have figured out why some splicing-based drugs tend to work better than others.

Key Points: 
  • CSHL Associate Professor Justin Kinney, Krainer, and postdoc Yuma Ishigami have figured out why some splicing-based drugs tend to work better than others.
  • To better understand how this drug works, the Kinney and Krainer labs analyzed risdiplam's interactions with RNA.
  • "Our new study provides insights into the action and specificity of splice-modifying drugs," Krainer says.
  • "This should facilitate the development of more effective drugs and drug combinations for a variety of diseases."

Great Lake Investments Successfully Completes Beechwood Place Development in Spring Lake Amidst Community Harmony

Retrieved on: 
Friday, February 23, 2024

SPRING LAKE, Mich., Feb. 22, 2024 /PRNewswire/ -- Great Lake Investments, a leading real estate development company in west Michigan, proudly announces the successful completion of the 32 condo Beechwood Place development in Spring Lake, demonstrating an innovative and harmonious approach to addressing the community's housing needs.

Key Points: 
  • SPRING LAKE, Mich., Feb. 22, 2024 /PRNewswire/ -- Great Lake Investments, a leading real estate development company in west Michigan, proudly announces the successful completion of the 32 condo Beechwood Place development in Spring Lake, demonstrating an innovative and harmonious approach to addressing the community's housing needs.
  • How did Great Lake Investments achieve this feat amidst Spring Lake's notorious pushback against development?
  • While other developers, such as Eastbrook, faced three years of contentious battles with Spring Lake over new home construction, Great Lake Investments took a different path by fostering collaboration with the community.
  • Great Lake Investments' approach serves as a model for balancing development goals with community interests, creating a win-win situation for all stakeholders involved.

How a mouse's brain bends time

Retrieved on: 
Tuesday, January 30, 2024

So the question is, how does the brain do it."

Key Points: 
  • So the question is, how does the brain do it."
  • Now, Banerjee and collaborators have uncovered a new clue that suggests the brain bends our processing of time to suit our needs.
  • It might help explain how time is computed in other parts of the brain, allowing us to adjust various behaviors accordingly.
  • If everything was a stimulus-response, with no opportunity for learning, nothing that changes, no long-term goals, we wouldn't need a brain.

These worms have rhythm

Retrieved on: 
Wednesday, December 27, 2023

COLD SPRING HARBOR, N.Y., Dec. 27, 2023 /PRNewswire/ -- There's a rhythm to developing life.

Key Points: 
  • COLD SPRING HARBOR, N.Y., Dec. 27, 2023 /PRNewswire/ -- There's a rhythm to developing life.
  • Losing the rhythm can lead to diseases like cancer.
  • Cold Spring Harbor Laboratory (CSHL) Professor Christopher Hammell has found that in the worm C. elegans, this genetic orchestra has no single conductor.
  • Understanding how the worm's clock is regulated could help explain how time affects development in other animals.

Can we crack this cancer's immune response?

Retrieved on: 
Wednesday, November 29, 2023

It's thought patients do not show a natural immune response to the cancer because the tumor environment somehow prevents that response.

Key Points: 
  • It's thought patients do not show a natural immune response to the cancer because the tumor environment somehow prevents that response.
  • Many are unconvinced that PDAC interacts with the immune system at all.
  • CSHL scientists have now confirmed that pancreatic cancer does trigger a response in our immune system.
  • The idea was that the synthetic antibodies would point the team toward the new PDAC antigen behind the body's immune response .

18th Double Helix Medals dinner raises more than $10 million

Retrieved on: 
Monday, November 27, 2023

COLD SPRING HARBOR, N.Y., Nov. 27, 2023 /PRNewswire/ -- On November 15, Cold Spring Harbor Laboratory (CSHL) held its 18th annual Double Helix Medals dinner (DHMD) at the American Museum of Natural History in New York City.

Key Points: 
  • COLD SPRING HARBOR, N.Y., Nov. 27, 2023 /PRNewswire/ -- On November 15, Cold Spring Harbor Laboratory (CSHL) held its 18th annual Double Helix Medals dinner (DHMD) at the American Museum of Natural History in New York City.
  • CBS journalist Lesley Stahl returned to emcee the awards dinner, which honored Neri Oxman & William Ackman and 2018 Nobel laureate Jim Allison.
  • After receiving the Double Helix Medal, Oxman and Ackman announced an extraordinary gift, further breaking the event's fundraising record to support scientific research and education at CSHL.
  • Since the inaugural gala in 2006 honoring Muhammed Ali, the DHMD has raised over $60 million to support CSHL's biological research and education programs.

Cold Spring Harbor Laboratory rolls out STEM 'Bicycle Principles'

Retrieved on: 
Tuesday, November 21, 2023

COLD SPRING HARBOR, N.Y., Nov. 21, 2023 /PRNewswire/ -- Success in science, technology, engineering, and mathematics (STEM) demands keeping up with the latest tools and techniques.

Key Points: 
  • COLD SPRING HARBOR, N.Y., Nov. 21, 2023 /PRNewswire/ -- Success in science, technology, engineering, and mathematics (STEM) demands keeping up with the latest tools and techniques.
  • Short training programs like webinars and boot camps have become a popular alternative among busy STEM professionals.
  • There's often no guarantee attendees will leave with the skills needed to advance their careers.
  • Williams is Assistant Director of Diversity and Research Readiness at the Cold Spring Harbor Laboratory (CSHL) DNA Learning Center .

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Retrieved on: 
Wednesday, November 15, 2023

TEL AVIV, Israel, Nov. 15, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted CM-101 Fast Track designation for the treatment in adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease that can result in liver transplant, cancer and early death.

Key Points: 
  • Fast Track is a process developed by the FDA to facilitate and expedite the development of new treatments that demonstrate a potential to address unmet medical needs in serious or life-threatening conditions.
  • Programs with Fast Track designation can benefit from early and more frequent interactions with the FDA during the clinical development process.
  • Therapeutic candidates with Fast Track designation may also be eligible for priority review and accelerated approval if supported by clinical data.
  • Patient enrollment in the trial is advancing towards completion and Chemomab anticipates reporting a top-line readout in the second half of 2024.

New Real-World Data Show TREMFYA® (guselkumab) Was Associated With Clinically Meaningful Improvements in Patient-Reported Outcomes for Adults Living With Active Psoriatic Arthritis

Retrieved on: 
Wednesday, November 8, 2023

SPRING HOUSE, Pa., Nov. 8, 2023 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced new data from the CorEvitas Psoriatic Arthritis (PsA) and Spondyloarthritis Registry that showed a substantial proportion of people living with treatment-resistant active PsA and using TREMFYA® (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months.1 Additionally, across the DISCOVER-1, DISCOVER-2 and COSMOS clinical trials, treatment with TREMFYA was associated with higher rates of clinically meaningful improvements in a composite assessment of patient-reported pain, fatigue, physical function, skin problems and PsA-related depression than placebo in the first assessment of the PsA 5-Thermometer Scale Domains (PsA-5T-Ds).2

Key Points: 
  • "People living with active psoriatic arthritis who are treatment-resistant need options that improve debilitating symptoms of their disease, like pain, physical function and fatigue," said Philip Mease, M.D., Swedish Medical Center/Providence St. Joseph Health and University of Washington in Seattle, Washington.a "It is important that we assess patient-reported outcomes in a real-world setting, ensuring that we address unmet needs for people living with this challenging disease."
  • "It is critical that we evaluate patient-reported outcomes to truly understand the lived experiences of patients and better develop and provide treatments in psoriatic disease."
  • Dr. Philip Mease is a paid consultant for Janssen.
  • He has not been compensated for any media work.

You say genome editing, I say natural mutation

Retrieved on: 
Wednesday, November 8, 2023

COLD SPRING HARBOR, N.Y., Nov. 8, 2023 /PRNewswire/ -- For tens of thousands of years, evolution shaped tomatoes through natural mutations .

Key Points: 
  • COLD SPRING HARBOR, N.Y., Nov. 8, 2023 /PRNewswire/ -- For tens of thousands of years, evolution shaped tomatoes through natural mutations .
  • Today, CRISPR genome editing allows us to make new crop mutations that improve traits even further.
  • And what if just one could dramatically alter the desired outcome of an engineered mutation?
  • (Natural mutation of this gene is known to increase fruit size.)